It's a good point Pixie and SC1 out-licensing into Asia always...

It's a good point Pixie and SC1 out-licensing into Asia always brings the bigger picture & the real value suitors may see - big pharma always likes to be able to extract maximum value out of deals or mitigating any risk more so by having more than one avenue to any investment. SM6 binds so well into SC1 when looking at the greater picture. Takeda already has Velcade for multiple melanoma & being a Japanese company is already neatly tucked into Asia. Amgen already has Rilotumumab in Phase III for gastric cancer and as we all know now the pending combination trial for SM6 with Kyprolis since acquiring Onyx.

Plenty of reasons that multiple parties could be using a wider ruler to go over the fine print.